BD ANNOUNCES RESULTS FOR 2012 THIRD FISCAL QUARTER
BD ANNOUNCES RESULTS FOR 2012 THIRD FISCAL QUARTER Reported results reflect reclassification of Discovery Labware unit as discontinued operations, excluding Advanced Bioprocessing. Third-quarter earnings per share of $1.59 include $1.52 from continuing operations and $0.07 from discontinued operations relating to the Discovery Labware unit. Franklin Lakes, NJ (August 2, 2012) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.981 billion for the third fiscal quarter ended June 30, 2012, representing an increase of 1.5 percent from the prior-year period, or 4.9 percent on a foreign currency-neutral basis. “We are very pleased with our third quarter results,” said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President. “As we anticipated, our revenue and earnings growth improved this quarter, demonstrating that our strategy implementation is on track and in line with our previously communicated expectations.” Update on Agreement to Sell Discovery Labware Unit, Excluding Advanced Bioprocessing In April 2012, the Company signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform. The transaction is expected to be completed by the end of calendar year 2012, subject to the satisfaction of customary closing conditions, including consultations and regulatory approvals. The results of operations associated with this disposal group have been reclassified as discontinued operations for all quarters and years referred to in this release. As illustrated on page 3 of the attached financial tables, diluted earnings per share for the third quarter of $1.59 less the $0.07 from discontinued operations resulted in earnings per share from continuing operations of $1.52.